Skip to main
INMD
INMD logo

Inmode Ltd (INMD) Stock Forecast & Price Target

Inmode Ltd (INMD) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 0%
Buy 25%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

InMode Ltd experienced a notable increase in its global installed base, with sales of 971 systems in 2Q25, bringing the total to approximately 28,855 units, indicating a 3.4% growth from the previous quarter. The company reported an operating margin of 27.5%, exceeding expectations and reflecting a year-over-year improvement of 40 basis points. Additionally, domestic sales reached $49.7 million, demonstrating a significant turnaround with a growth rate of 9%, compared to a decline of 7% in the prior quarter, underscoring the robust demand in the aesthetics market.

Bears say

InMode Ltd is anticipated to experience a contraction in its margins, despite currently holding among the highest margins in the med tech sector, which could lead to its earnings per share (EPS) growth lagging behind revenue growth. The company's bearish outlook includes expectations of a revenue compound annual growth rate (CAGR) of less than 5% over the next few years, driven by weaker growth from existing products and slower than anticipated adoption of new offerings. Additionally, while operating margins have improved year-over-year, gross margins have decreased, indicating potential pressure on profitability moving forward.

Inmode Ltd (INMD) has been analyzed by 4 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 25% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inmode Ltd (INMD) Forecast

Analysts have given Inmode Ltd (INMD) a Hold based on their latest research and market trends.

According to 4 analysts, Inmode Ltd (INMD) has a Hold consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inmode Ltd (INMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.